381 related articles for article (PubMed ID: 28935492)
1. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.
Iaccarino L; Andreoli L; Bocci EB; Bortoluzzi A; Ceccarelli F; Conti F; De Angelis R; De Marchi G; De Vita S; Di Matteo A; Emmi G; Emmi L; Gatto M; Gerli R; Gerosa M; Govoni M; Larosa M; Meroni PL; Mosca M; Pazzola G; Reggia R; Saccon F; Salvarani C; Tani C; Zen M; Frigo AC; Tincani A; Doria A
J Autoimmun; 2018 Jan; 86():1-8. PubMed ID: 28935492
[TBL] [Abstract][Full Text] [Related]
2. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
[TBL] [Abstract][Full Text] [Related]
3. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
[TBL] [Abstract][Full Text] [Related]
4. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting.
Anjo C; Mascaró JM; Espinosa G; Cervera R
Scand J Rheumatol; 2019 Nov; 48(6):469-473. PubMed ID: 31264525
[No Abstract] [Full Text] [Related]
6. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
Gatto M; Saccon F; Andreoli L; Bartoloni E; Benvenuti F; Bortoluzzi A; Bozzolo E; Brunetta E; Canti V; Cardinaletti P; Ceccarelli F; Ciccia F; Conti F; De Marchi G; de Paulis A; De Vita S; Emmi G; Faggioli P; Fasano S; Fredi M; Gabrielli A; Gasparotto M; Gerli R; Gerosa M; Govoni M; Gremese E; Laria A; Larosa M; Mosca M; Orsolini G; Pazzola G; Petricca L; Ramirez GA; Regola F; Rossi FW; Rossini M; Salvarani C; Scarpato S; Tani C; Tincani A; Ubiali T; Urban ML; Zen M; Doria A; Iaccarino L
J Autoimmun; 2021 Nov; 124():102729. PubMed ID: 34600347
[TBL] [Abstract][Full Text] [Related]
7. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
[TBL] [Abstract][Full Text] [Related]
9. Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study.
Fernandes BM; Barreira S; Fonseca JE; Cunha M; Santos MJ; Gonçalves N; Fernandes AL; Rodrigues J; Fontes T; Costa L; Bernardes M
Acta Reumatol Port; 2020; 45(3):170-176. PubMed ID: 33139681
[TBL] [Abstract][Full Text] [Related]
10. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
[TBL] [Abstract][Full Text] [Related]
11. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
12. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
[TBL] [Abstract][Full Text] [Related]
13. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Rheumatology (Oxford); 2019 Dec; 58(12):2170-2176. PubMed ID: 31157891
[TBL] [Abstract][Full Text] [Related]
14. [Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].
Garval E; Pennaforte JL; Jaussaud R; Servettaz A; Bernard P; Reguiai Z
Ann Dermatol Venereol; 2018 Jan; 145(1):5-12. PubMed ID: 29113694
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses.
Zheng J; Gu J; Su Y; Li Y; Li X; Xiong C; Cao H; Quasny H; Chu M; Curtis P; DeRose K; Kurrasch R; Meizlik P; Roth DA; Zhang F
Mod Rheumatol; 2023 Jul; 33(4):751-757. PubMed ID: 36208293
[TBL] [Abstract][Full Text] [Related]
16. Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids.
Lee YJ; Ahn SM; Hong S; Oh JS; Lee CK; Yoo B; Kim YG
Korean J Intern Med; 2024 Mar; 39(2):338-346. PubMed ID: 38031366
[TBL] [Abstract][Full Text] [Related]
17. Belimumab for the treatment of recalcitrant cutaneous lupus.
Vashisht P; Borghoff K; O'Dell JR; Hearth-Holmes M
Lupus; 2017 Jul; 26(8):857-864. PubMed ID: 28121495
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
von Kempis J; Duetsch S; Reuschling N; Villiger R; Villiger PM; Vallelian F; Schaer DJ; Mueller RB
Swiss Med Wkly; 2019 Feb; 149():w20022. PubMed ID: 30852830
[TBL] [Abstract][Full Text] [Related]
20. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
Touma Z; Gladman DD; Ibañez D; Taghavi-Zadeh S; Urowitz MB
J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
